Cancerbackup: References

Skip the page content navigation if you do not require links to content sections within this page.

Page Content Navigation

Skip the main banner if you do not want to read it as the next section.

Page Banner

Want to speak to a specialist cancer nurse? Call free on 0808 800 1234


Skip the main content if you do not want to read it as the next section.

References

  1. Henning Mouridsen et al (2001) Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer; results of a phase lll study of the International Letrozole Breast Cancer Group, Journal of Clinical Oncology, Vol 19 (10) pp 2596-2606
  2. The ATAC Trialists Group (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer; first results of the ATAC randomized trial, The Lancet, vol 359, pp2131-2139
  3. ATAC Trialists group (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer, The Lancet, vol 365, pp60-62
  4. http://www.breastcancerupdate.com/bcu2005/2_surgeons/howell.htm
  5. Thurlimann B et al (2005) BIG 1-98: Randomised double-blind phase III study to evaluate letrozole (L) vs tamoxifen (T) as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer, Proc Am Soc Clin Oncol, vol 23 abtr 511
  6. The Breast International Group (BIG) 1-98 Collaborative Group (2005) A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast Cancer, NEJM, vol 353 (26) pp2747-2757
  7. Coombes RC et al (2004) A Randomised Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer, New England Journal of Medicine, vol 350 (11) pp 1081-1092
  8. Jakesz R et al (2005) Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial, Lancet, vol 366, pp455-462
  9. Goss P et al (2003) A Randomised Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer, New England Journal of Medicine, vol 349 (19) pp 1793-1802
  10. Winer Eric P et al (2005) American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer; Status Report 2004, Journal of Clinical Oncology, vol 23 (3) pp 619-629
  11. Hillner Bruce E et al (2003) American Society of Clinical Oncology 2003 Update on the role of bisphosphonates and bone health issues in women with breast cancer, JCO vol 21 (21) pp4042-4057
  12. Ellis Matthew J (2001) Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for Erb-1- and/or Erb-2-positive, Estrogen receptor positive primary breast cancer: Evidence from a phase lll randomized trial, JCO vol 19 (18) pp3808-3816
  13. Smith Ian E et al (2005) Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined With Tamoxifen (IMPACT) Multicenter Double Blind Randomized Trial, JCO, Vol 23 (22) pp5108-5116

Content last reviewed: 01 July 2006
Page last modified: 19 April 2007

Get support

Look for other people in the same situation on our What Now? community - read their blogs or talk to them in our chat rooms.

Find out about other ways to get support on the main Macmillan website.